Evidence map›Paper›PMID 40382467›Full record

ArticleScientific reports2025

Natural, vaccine-induced immunity and the probability of experiencing SARS-CoV-2 infection in a household cohort in Rio de Janeiro.

Michele F B da Silva, Lusiele Guaraldo, Leonardo Soares Bastos, Heloisa F P Santos, Otávio M Espíndola, Paola Cristina Resende, Stephanie L S Penetra, Anielle Pina-Costa, Isabella C V de Moraes, Guilherme A Calvet and 4 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Michele F B da SilvaEvandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (Fiocruz), Avenida Brasil 4365 - Manguinhos, Rio de Janeiro, RJ, 21040-3608, Brazil.
Lusiele GuaraldoEvandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (Fiocruz), Avenida Brasil 4365 - Manguinhos, Rio de Janeiro, RJ, 21040-3608, Brazil.
Leonardo Soares BastosScientific Computing Program (PROCC), Fiocruz, Avenida Brasil 4365 - Manguinhos , Rio de Janeiro, 21040-3608, RJ, Brazil.
Heloisa F P SantosEvandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (Fiocruz), Avenida Brasil 4365 - Manguinhos, Rio de Janeiro, RJ, 21040-3608, Brazil.
Otávio M EspíndolaEvandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (Fiocruz), Avenida Brasil 4365 - Manguinhos, Rio de Janeiro, RJ, 21040-3608, Brazil.
Paola Cristina ResendeLaboratory of Respiratory Viruses and Measles National Influenza Centre (GISRS-WHO) - Americas Regional Reference Lab for Measles and Rubella - Reference Laboratory for COVID- 19 (WHO), Oswaldo Cruz Institute (IOC), Fiocruz. Avenida Brasil 4365 - Manguinhos, Rio de Janeiro, RJ, 21040-3608, Brazil.
Stephanie L S PenetraEvandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (Fiocruz), Avenida Brasil 4365 - Manguinhos, Rio de Janeiro, RJ, 21040-3608, Brazil.
Anielle Pina-CostaEvandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (Fiocruz), Avenida Brasil 4365 - Manguinhos, Rio de Janeiro, RJ, 21040-3608, Brazil.
Isabella C V de MoraesEvandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (Fiocruz), Avenida Brasil 4365 - Manguinhos, Rio de Janeiro, RJ, 21040-3608, Brazil.
Guilherme A CalvetEvandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (Fiocruz), Avenida Brasil 4365 - Manguinhos, Rio de Janeiro, RJ, 21040-3608, Brazil.
Trevon L FullerEvandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (Fiocruz), Avenida Brasil 4365 - Manguinhos, Rio de Janeiro, RJ, 21040-3608, Brazil.
Marilda M SiqueiraLaboratory of Respiratory Viruses and Measles National Influenza Centre (GISRS-WHO) - Americas Regional Reference Lab for Measles and Rubella - Reference Laboratory for COVID- 19 (WHO), Oswaldo Cruz Institute (IOC), Fiocruz. Avenida Brasil 4365 - Manguinhos, Rio de Janeiro, RJ, 21040-3608, Brazil.
Marilia Sá CarvalhoScientific Computing Program (PROCC), Fiocruz, Avenida Brasil 4365 - Manguinhos , Rio de Janeiro, 21040-3608, RJ, Brazil.
Patricia BrasilEvandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (Fiocruz), Avenida Brasil 4365 - Manguinhos, Rio de Janeiro, RJ, 21040-3608, Brazil. patricia.brasil@ini.fiocruz.br.

Funding

CNPQ CABBIO 423857/2021-5CNPq COVID-19 MCTI402457/2020-0 and 403276/2020-9CNPq productivity research fellowship 313403/2018-0CNPQ productivity research fellowship 311759/2022-0Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 001INOVA Fiocruz VPPCB-005-FIO-20-2 and VPPCB-007-FIO-18-2-30National Council for Scientific and Technological Development (CNPq) 409108/2022-7 and 311562/2021-3National Institute for Health and Care Research (NIHR UK) MR/V033530/1Orchestra 101016167The Carlos Chagas Foundation for the Advancement of Science of the State of Rio de Janeiro (FAPERJ) E26/210.196/2020 and E-26/211.125/2021The Carlos Chagas Foundation for the Advancement of Science of the State of Rio de Janeiro (FAPERJ) E-26/211.565/2019 and E-26/200.935/2022
6 · The paper itself

Abstract

The impact of COVID-19 vaccines on real-world transmission remains poorly understood and represents a key public health challenge. This study aimed to investigate natural, vaccine-induced immunity and the probability of experiencing SARS-CoV-2 infection in a cohort of families living in Rio de Janeiro. The participants were categorized into immune groups based on recent infection (within the past 9 months) and vaccination status, considering the type of vaccine received, the number of doses, and the strength of their immune response over time. We estimated the transmission probability within clusters using a multivariate model. From May 2020 to June 2023, we enrolled 669 individuals from 182 households; 272 clusters and 288 index cases were identified. Household transmission occurred in 124 (45.6%) clusters. During the pre-VoC period we did not find any factors associated with transmission. In the Gamma/Delta period, previous infections reduced the probability of transmission (OR = 0.088; 95%CI 0.023-0.341), while in the Omicron period, having a healthcare worker in the household (OR = 0.486; 95%CI 0.256-0.921) and hybrid immunity (OR = 0.095; 95%CI 0.010-0.924) decreased the probability of transmission. Our findings provide strong support for the protective effect of regular vaccination against household transmission in a cohort of families exposed to successive SARS-CoV-2 variants.

Indexed as

COVID-19COVID-19 VaccinesSARS-CoV-2AdolescentAdultAgedBrazilChildChild, PreschoolCohort StudiesFamily CharacteristicsFemaleHumansMaleMiddle AgedVaccinationCOVID-19 VaccinesCohort studyCOVID-19COVID-19 vaccineHousehold transmissionImmunitySARS-CoV-2 variants

Identifiers

PMID40382467
PMCPMC12085559

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.